Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA) : long-term survival results from the randomized phase 3 PHILA trial

Published: 30 December 2025| Version 1 | DOI: 10.17632/62224ppy2z.1
Contributors:
Fei Ma, Min Yan, Wei Li, Quchang Ouyang, Zhongsheng Tong, Yuee Teng, Yongsheng Wang, Shusen Wang, Cuizhi Geng, Ting Luo, Jincai Zhong, Qingyuan Zhang, Qiang Liu, Xiaohua Zeng, Tao Sun, Qinguo Mo, Shoubing Zhou, Peidong Li, Jing Cheng, Xiaojia Wang, Jianyun Nie, Jin Yang, Xinhong Wu, Xinshuai Wang, Huiping Li, Guangyu Yao, Yang Fan, Jiaman Lin, Xiaoyu Zhu, Binghe Xu

Description

This database derives from the multicentre, double-blind, randomised, open label phase 3 PHILA trial evaluating pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. The shared database includes patient level analysis datasets (ADSL, ADTTE, ADAE, ADCM, ADSLRS, ADEX), covering anonymised subject identifiers, demographics, baseline disease characteristics, treatment allocation and exposure, tumour response assessments, time-to-event outcomes, adverse events, medical history, concomitant medications and follow-up anti-cancer therapies.

Files

Categories

HER2-Positive Breast Cancer, Tyrosine Kinase Inhibitor, Randomized Clinical Trial

Funders

  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Licence